Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib

An 84-year-old male had a recurrence after surgical resection against Stage IIIA pulmonary adenocarcinoma and was treated with crizotinib due to harboring the anaplastic lymphoma kinase fusion gene. The patient exhibited crizotinib-induced interstitial lung disease (ILD), and alectinib was administe...

Full description

Saved in:
Bibliographic Details
Published inJournal of cancer research and therapeutics Vol. 16; no. 4; pp. 919 - 921
Main Authors Kaira, Kyoichi, Naruse, Ichiro, Shimizu, Kimihiro, Asao, Takayuki
Format Journal Article
LanguageEnglish
Published Mumbai Wolters Kluwer India Pvt. Ltd 01.10.2020
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Subjects
Alectinib
Cancer genetics
Care and treatment
Crizotinib
Lung cancer
Lung diseases
Lymphomas
Non-small cell lung cancer
Targeted cancer therapy
lung cancer
interstitial lung disease
Anaplastic lymphoma kinase
Online AccessGet full text

Cover

More Information
Summary:An 84-year-old male had a recurrence after surgical resection against Stage IIIA pulmonary adenocarcinoma and was treated with crizotinib due to harboring the anaplastic lymphoma kinase fusion gene. The patient exhibited crizotinib-induced interstitial lung disease (ILD), and alectinib was administered because of progressive disease. However, ILD appeared in both lungs again after alectinib treatment. This is the first case of ILD, resulting from alectinib administration after crizotinib-induced ILD. We should pay careful attention to patients who are treated with alectinib after crizotinib-induced ILD.
ISSN:0973-1482
1998-4138
DOI:10.4103/jcrt.jcrt_985_15